1. Scrip
  2. >>Therapy Areas

Bayer Heralds Potential Of BlueRock Parkinson's Stem Cell Therapy

Early-Stage Signs Show Promise

 
• By Kevin Grogan

Bayer pharma research head Christian Rommel has told Scrip he was excited about the Phase I data on Parkinson's disease prospect bemdaneprocel, which is comprised of dopamine-producing neurons derived from pluripotent stem cells, but also advocated caution at this early stage.

Christian Rommel
Christian Rommel • Source: Bayer

The excitement surrounding positive data from a small early-stage study evaluating Bayer AG subsidary BlueRock Therapeutics LP's bemdaneprocel for Parkinson's disease is merited, according to the German major's pharma R&D chief Christian Rommel, while stressing the need for patience in advancing the stem cell-derived therapy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas